Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Kanglaite for Rising PSA in Prostate Cancer
NCT01483586Phase 2
Key facts
- Status
- Terminated
- Start
- Nov 2011
- Primary completion
- Dec 2013
- Countries
- 1
- Modality
- HM (Herbal Medicine)
- Drugs
- kanglaite
- Conditions
- prostate cancer (PCa)
01
Overview
Phase 2, randomised, open-label trial of kanglaite in prostate cancer (PCa) (2 arms), sponsored by Zhejiang Kanglaite Pharmaceutical Co., Ltd. Primary endpoint: Prostate Specific Antigen Doubling Time at 12 months. Started Nov 2011; status: terminated.
02
Design
2 arms- Study design
- RandomizedOpen-label
KLTc High Dose
6 KLTc gelcaps taken four times a day
KLTc Low Dose
3 KLTc gelcaps taken four times a day
03
Endpoints
Primary
Prostate Specific Antigen Doubling Time
Secondary
PSA Objective Response
KLTc Intake Compliance
Beyond the preview
Go deeper on NCT01483586.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01483586.